

Press Release

SYGNIS AG to Present at Upcoming Investor Conferences

Madrid, Spain, and Heidelberg, Germany, November 18, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the attendance at two major German investor conferences in November and December 2016.

German Equity Forum hosted by Deutsche Börse AG

Date of attendance: 21 and 22 November 2016

Presentation time: Monday, 21 November 2016, 17:00 - 17:30 pm CET, Room Oslo

Venue: Frankfurt/Main, Germany, Sheraton Frankfurt Airport Hotel and Conference Center

Presenting and available for meetings: Dr. Heikki Lanckriet, Co-CEO and CSO, Pilar de la Huerta, Co-CEO/CFO

More information: <http://www.eigenkapitalforum.com/>

22nd Munich Capital Markets Conference (MKK) hosted by GBC AG

Date of attendance: 7 and 8 December 2016

Presentation time: Tuesday, 7 December 2016, 12:20 - 13:00 pm CET, Room GBC III

Venue: Munich, Germany, The Charles Hotel

Presenting and available for meetings: Dr. Heikki Lanckriet, Co-CEO and CSO, Pilar de la Huerta, CEO/CFO

More information: <http://www.mkk-investor.de/>

If you would like to meet us, please contact for both conferences: contact@mc-services.eu or via phone: +49 89 210 228-0.

For further information, please contact:

SYGNIS AG

Pilar de la Huerta

Co-CEO/CFO

Phone: +34 91 192 36 50

Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales

offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###